Skip to main content
Premium Trial:

Request an Annual Quote

Raymond James Downgrades Genomic Health to Market Perform

NEW YORK (GenomeWeb) – Raymond James today downgraded Genomic Health to Market Perform from Outperform, noting that the company's stock has essentially reached its prior price target with limited catalysts for positive near-term estimate revisions.

In a note to investors, analyst Nicholas Jansen said 2017 is shaking out to be more of a "transition" year than an "upside to numbers" year, with growth accelerants either already encapsulated by the price target or more likely to influence Genomic Health's revenues in 2018.

Although Genomic Health continues to expect an expansion of Medicare coverage for its prostate cancer test before the end of the first half of this year, Jansen said that this is already included in its guidance, meaning there is little upside "given that each passing day limits the quarterly contribution."

Meanwhile, other drivers expected later this year — including new data from the TAILORx trial on intermediate risk-score patients, and reimbursement for testing in Germany —  are not likely to actually begin to affect Genomic Health's business until 2018.

"The UK and France are certainly contributing … but meaningful German reimbursement will need the TAILORx intermediate risk data and is thus a 2018 event in all likelihood," Jansen wrote.

However, he made clear that the downgrade is not a negative call on Genomic Health's upcoming Q1 earnings release.

Genomic Health's shares fell almost 3 percent to $32.07 in Wednesday morning trading on the New York Stock Exchange.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.